Compare DSY & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DSY | RFL |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 61.1M |
| IPO Year | 2023 | 2017 |
| Metric | DSY | RFL |
|---|---|---|
| Price | $3.29 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.0K | 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.17 | $1.12 |
| 52 Week High | $4.03 | $3.19 |
| Indicator | DSY | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 71.85 |
| Support Level | $0.33 | $1.41 |
| Resistance Level | $4.01 | $1.64 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 80.83 | 73.17 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.